In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Alnylam Pharma (ALNY – Research Report), with a price target of $287.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Michael Ulz has given his Hold rating due to a combination of factors including Alnylam Pharma’s recent financial performance and market dynamics. The company’s TTR franchise sales were in line with expectations, showing a steady growth trajectory both quarterly and annually. This indicates a stable demand for their products, particularly Amvuttra, which has seen a significant increase in demand in the US market.
Despite these positive trends, Ulz remains cautious due to uncertainties surrounding the early launch of Amvuttra in the TTR-CM market. While the initial trends are encouraging, with broad use and access reported, there are still potential risks that could impact future performance. Additionally, the company’s reiterated guidance for 2025 suggests strong growth, but the execution of these plans remains to be seen. These factors contribute to the decision to maintain a Hold rating, reflecting a balanced view of the potential risks and rewards associated with Alnylam Pharma’s stock.
In another report released on April 28, Cantor Fitzgerald also initiated coverage with a Hold rating on the stock with a $250.00 price target.
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year.